RAD
RADIOPHARM THERANOSTICS LIMITED
$0.0040
0.00%
Market cap
$19M
Turnover
$4,371
Last price
$0.0040
Day change
0.00%
Announcements
15
Range, past year
Open 0.023 · Low 0.003 · Now 0.004 · High 0.040
Open RAD in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
RAD momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
32/100
Wyckoff phase
Accumulation6d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+0.0%
1 Month
+0.0%
1 Year
-81.8%
RSI
45
Avg daily range
23.6%
RADIOPHARM THERANOSTICS LIMITED scores 32 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 6 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.90 — highly linear uptrend
Points to watch
- 60d drawdown -70.0%
- High volatility (ATR 23.6%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
RAD announcements
Recent price-sensitive releases.
- 2026-11-04 RAD Alignment with US FDA for Development of RAD101 Progress Report
- 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-26 Radiopharm receives $8M advance on FY26 R&D tax incentive Issued Capital - Other
- 2026-08-28 Appendix 4E and Preliminary Final Report Preliminary Final Report
- 2026-08-26 RAD Doses First Patient in Second Cohort of BetaBart (RV-01) Progress Report
- 2026-08-20 RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial Progress Report
- 2026-08-17 RAD to meet with US FDA to align on RAD 101 Phase 3 Trial Progress Report
More Health Care stocks
Most traded in the same sector.